Venus Medtech Email Format
Medical Equipment ManufacturingZhejiang, China51-200 Employees
Venus Medtech (Hangzhou) Inc. is a medical device manufacturer focused on transcatheter structural heart therapies, based in Hangzhou, Zhejiang. It developed VenusA-Valve, a self-developed transcatheter aortic valve that was approved by the National Medical Products Administration and commercialized in China. The company has been described as a leading transcatheter heart valve player in China by implantation volume in 2018, serving hospitals and clinicians performing these procedures. The firm expanded its portfolio through the 2018 acquisition of Keystone Heart Ltd. In 2026, Venus Medtech held its first Global Partner Summit in Paris to discuss international growth and portfolio expansion in structural heart disease. Regulatory milestones include FDA IDE approval for VenusP-Valve, reflecting ongoing development of transcatheter valve therapies beyond domestic markets.